Status: Not yet recruiting
GC012F in Patients With Autoimmune Diseases
This is an open-label, early exploratory main clinical study to evaluate the safety and efficacy of GC012F Injection in subjects with autoimmune diseases (AID), as well as to assess its pharmacokinetic (PK) and pharmacodynamic (PD) profiles.
Participants needed: 15
Trial details
Phase: Early Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Qiong FuUpdated: Jul 18, 2025
Eligibility criteria
The subject or legal representative voluntarily signs the written informed conse... [+11]
History of severe hypersensitivity or allergy; [+25]